Head-to-head · WeighScore
FuturHealth vs Transparent Meds
The verdict
FuturHealth takes it — 65.6/100 to 61.9/100.
FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FuturHealth | Transparent Meds |
|---|---|---|
| WeighScore | 65.6/100 | 61.9/100 |
| Grade | C | C |
| Scorecard rank | #215 | #282 |
| Semaglutide | $199/mo (compounded) | $229/mo (promotional rate, compounded) |
| Tirzepatide | Not disclosed | $349/mo (compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
Graded #215 · C
Strengths
- LegitScript Certified and HITRUST Certified
- Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
- Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
- Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths
Where it loses points
- Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
- BBB complaints describe recurring charges without medication received — confirm cancellation flow first
- Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
- Pricing not shown until after the qualification questionnaire or portal login
- Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Graded #282 · C
Strengths
- Transparent, upfront monthly pricing — intro $149/mo for compounded semaglutide and $249/mo for tirzepatide (regular $229 / $349)
- Clean, modern telehealth experience with a quick eligibility quiz and clinician review before any prescription
- HIPAA-compliant and displays a LegitScript-style verification seal
Where it loses points
- Headline prices are intro first-month fees — the regular monthly cost is higher ($229 semaglutide, $349 tirzepatide)
- Connector model that pairs you with licensed providers; it doesn't name its compounding pharmacy
- Doesn't publish the states it serves, so confirm availability before signing up
- Compounded semaglutide and tirzepatide injections only — no oral, brand-name, or insurance options
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.